Boehringer Ingelheim Tipranavir NDA Could Signal Novel HIV Salvage Option
This article was originally published in The Pink Sheet Daily
Executive Summary
Non-peptidic protease inhibitor is “potent new treatment” for multi-drug-resistant HIV strains, firm says. NDA seeks accelerated approval and priority review for treatment of HIV-1 in combination with antiretrovirals in PI-experienced patients.
You may also be interested in...
Boehringer Ingelheim Aptivus To Get FDA Advisory Committee Review In May
Tipranavir will be considered by FDA's Antiviral Drugs Advisory Committee for the treatment of patients with multi-drug-resistant HIV. In clinical trials, use of the protease inhibitor was associated with GI adverse events and elevated triglycerides.
Pfizer Looks To Enter Oral Anti-Thrombotic Market Through Schering AG Deal
Company in-licenses Schering AG’s preclinical oral ADP receptor antagonist line; agents are targeted for chronic use in prophylaxis of arterial thrombosis and other CV events. Pfizer has one marketed anti-thrombotic, none in clinical development.